Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Read More
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Read MoreThe acquisition will help build Lilly’s infectious disease portfolio
Read MoreThe acquisition will advance innovation for patients with rare skin diseases
Read MoreThe companies aim to advance treatments for narcolepsy and other sleep-wake disorders
Read MoreThe deal will enhance Biogen’s growth portfolio in immunology and rare disease
Read MoreThe acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Read MoreExl-111, a potential treatment included in the deal, is a central factor in many allergic diseases
Read MoreThe oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study
Read MorePH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
Read MoreMultiple Ventyx drugs are currently in phase 2 development for inflammatory disease
Read MoreUS tariffs on UK-produced pharmaceuticals will remain at zero for three years
Read MoreThe Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer
Read More
